Fasudil is under clinical development by Woolsey Pharmaceuticals and currently in Phase II for Dementia. According to GlobalData, Phase II drugs for Dementia have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fasudil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fasudil overview

Fasudil (Eril) is a vasodilator agent. It was formulated as injectable solution and powder for solution for intravenous route of administration. Eril is indicated for the improvement of cerebral ischemic symptoms accompanying the cerebral vasospasm and its subarachnoid hemorrhage surgery.

AT-877 (fasudil) is under development for the treatment of amyotropic lateral sclerosis, frontemporal dementia, progressive supranuclear palsy, corticobasal degeneration and Huntington's disease. It was also under development for pulmonary arterial hypertension, acute cerebral infarction, angina pectoris, atherosclerosis and spinal cord injury.

Woolsey Pharmaceuticals overview

Woolsey Pharmaceuticals specializes in reinventing ways to treat some of the world’s most challenging diseases. The company is headquartered in New York City, New York, the US

For a complete picture of Fasudil’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.